Diamond-Blackfan anemia pathophysiology: Difference between revisions
Jump to navigation
Jump to search
| Line 8: | Line 8: | ||
==Pathophysiology== | ==Pathophysiology== | ||
*Diamond Blackfan anemia is characterized by a block in erythropoiesis which is due to the ribosomal protein gene mutation in about 80-85% of those affected.DBA is most frequently due to a sporadic mutation (55%) in genes encoding several different ribosomal proteins, although based on the latest studies, approximately 40 – 45% of DBA cases are hereditary which are inherited with autosomal dominant inheritance which means that a single copy of an altered gene in each cell is adequate to cause the disorder.<ref name="pmid22160079">{{cite journal |vauthors=Ball S |title=Diamond Blackfan anemia |journal=Hematology Am Soc Hematol Educ Program |volume=2011 |issue= |pages=487–91 |date=2011 |pmid=22160079 |doi=10.1182/asheducation-2011.1.487 |url=}}</ref><ref name="pmid23744582">{{cite journal |vauthors=Garçon L, Ge J, Manjunath SH, Mills JA, Apicella M, Parikh S, Sullivan LM, Podsakoff GM, Gadue P, French DL, Mason PJ, Bessler M, Weiss MJ |title=Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients |journal=Blood |volume=122 |issue=6 |pages=912–21 |date=August 2013 |pmid=23744582 |pmc=3739037 |doi=10.1182/blood-2013-01-478321 |url=}}</ref> and they have a family history of the disease with varying phenotypes.<ref name="pmid30228860">{{cite journal |vauthors=Da Costa L, Narla A, Mohandas N |title=An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia |journal=F1000Res |volume=7 |issue= |pages= |date=2018 |pmid=30228860 |pmc=6117846 |doi=10.12688/f1000research.15542.1 |url=}}</ref> about 25% of patients have mutations in the [[ribosomal|ribosome]] protein S19 (RPS19) gene on chromosome 19 at [[cytogenetic]] position 19q13.2 which is responsible for a defect in rRNA maturation. However, the disease characterized by genetic [[heterogeneity]] and other mutated genes also been found in RPL5, RPL11, RPL35A, RPS7, RPS10, RPS17, RPS24, and RPS26, and rarely in RPL15, RPL17, RPL19, RPL26, RPL27, RPL31, RPS15A, RPS20, RPS27, RPS28, RPS29, and "non-RP" genes such as TSR2 and GATA1. TSR2 playS a role in ribosome biogenesis since it is involved in the pre-rRNA processing and binds to RPS26 and GATA1 which is the major erythroid transcription factor and plays a critical role in regulating normal erythroid differentiation by activating an array of erythroid genes. In the remaining 10-15% of DBA cases, no abnormal genes have yet been identified. | *Diamond Blackfan anemia is characterized by a block in erythropoiesis which is due to the ribosomal protein gene mutation in about 80-85% of those affected.DBA is most frequently due to a sporadic mutation (55%) in genes encoding several different ribosomal proteins, although based on the latest studies, approximately 40 – 45% of DBA cases are hereditary which are inherited with autosomal dominant inheritance which means that a single copy of an altered gene in each cell is adequate to cause the disorder.<ref name="pmid22160079">{{cite journal |vauthors=Ball S |title=Diamond Blackfan anemia |journal=Hematology Am Soc Hematol Educ Program |volume=2011 |issue= |pages=487–91 |date=2011 |pmid=22160079 |doi=10.1182/asheducation-2011.1.487 |url=}}</ref><ref name="pmid23744582">{{cite journal |vauthors=Garçon L, Ge J, Manjunath SH, Mills JA, Apicella M, Parikh S, Sullivan LM, Podsakoff GM, Gadue P, French DL, Mason PJ, Bessler M, Weiss MJ |title=Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients |journal=Blood |volume=122 |issue=6 |pages=912–21 |date=August 2013 |pmid=23744582 |pmc=3739037 |doi=10.1182/blood-2013-01-478321 |url=}}</ref> and they have a family history of the disease with varying phenotypes.<ref name="pmid30228860">{{cite journal |vauthors=Da Costa L, Narla A, Mohandas N |title=An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia |journal=F1000Res |volume=7 |issue= |pages= |date=2018 |pmid=30228860 |pmc=6117846 |doi=10.12688/f1000research.15542.1 |url=}}</ref> about 25% of patients have mutations in the [[ribosomal|ribosome]] protein S19 (RPS19) gene on chromosome 19 at [[cytogenetic]] position 19q13.2 which is responsible for a defect in rRNA maturation. However, the disease characterized by genetic [[heterogeneity]] and other mutated genes also been found in RPL5, RPL11, RPL35A, RPS7, RPS10, RPS17, RPS24, and RPS26, and rarely in RPL15, RPL17, RPL19, RPL26, RPL27, RPL31, RPS15A, RPS20, RPS27, RPS28, RPS29, and "non-RP" genes such as TSR2 and GATA1. TSR2 playS a role in ribosome biogenesis since it is involved in the pre-rRNA processing and binds to RPS26 and GATA1 which is the major erythroid transcription factor and plays a critical role in regulating normal erythroid differentiation by activating an array of erythroid genes. In the remaining 10-15% of DBA cases, no abnormal genes have yet been identified. It is likely that mutations are in a regulatory region including intronic regions and promoters in one of the known RP genes may account for the DBA phenotype. <ref name="pmid30228860">{{cite journal |vauthors=Da Costa L, Narla A, Mohandas N |title=An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia |journal=F1000Res |volume=7 |issue= |pages= |date=2018 |pmid=30228860 |pmc=6117846 |doi=10.12688/f1000research.15542.1 |url=}}</ref> | ||
*Mutations in RP genes have been confirmed to be the direct cause of faulty erythropoiesis and anemia | *Mutations in RP genes have been confirmed to be the direct cause of faulty erythropoiesis and anemia.<ref name="pmid23463023">{{cite journal |vauthors=Vlachos A, Dahl N, Dianzani I, Lipton JM |title=Clinical utility gene card for: Diamond-Blackfan anemia--update 2013 |journal=Eur. J. Hum. Genet. |volume=21 |issue=10 |pages= |date=October 2013 |pmid=23463023 |pmc=3778360 |doi=10.1038/ejhg.2013.34 |url=}}</ref>.A generally documented pathogenetic hypothesis implies that a defective ribosome biosynthesis leads to apoptosis in erythroid progenitors which in turn is leading to erythroid failure. This mechanism has been named ‘‘ribosomal stress . in ‘‘ribosomal stress, reduced RP synthesis activates p53 that induces the downstream events and leads to cell cycle termination or apoptosis. Finally, this phenomenon results in the DBA phenotype of anemia, deprived growth, and results in congenital abnormalities. Mutated RP genes in DBA encode ribosomal proteins which are involved in either the small (RPS) or large (RPL) subunits of these proteins and the scarcity of these proteins can cause the development of the disease.<ref name="pmid19327583">{{cite journal |vauthors=Lipton JM, Ellis SR |title=Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis |journal=Hematol. Oncol. Clin. North Am. |volume=23 |issue=2 |pages=261–82 |date=April 2009 |pmid=19327583 |pmc=2886591 |doi=10.1016/j.hoc.2009.01.004 |url=}}</ref> | ||
==References== | ==References== | ||
Revision as of 20:28, 4 August 2020
|
Diamond-Blackfan anemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diamond-Blackfan anemia pathophysiology On the Web |
|
American Roentgen Ray Society Images of Diamond-Blackfan anemia pathophysiology |
|
Risk calculators and risk factors for Diamond-Blackfan anemia pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pathophysiology
- Diamond Blackfan anemia is characterized by a block in erythropoiesis which is due to the ribosomal protein gene mutation in about 80-85% of those affected.DBA is most frequently due to a sporadic mutation (55%) in genes encoding several different ribosomal proteins, although based on the latest studies, approximately 40 – 45% of DBA cases are hereditary which are inherited with autosomal dominant inheritance which means that a single copy of an altered gene in each cell is adequate to cause the disorder.[1][2] and they have a family history of the disease with varying phenotypes.[3] about 25% of patients have mutations in the ribosome protein S19 (RPS19) gene on chromosome 19 at cytogenetic position 19q13.2 which is responsible for a defect in rRNA maturation. However, the disease characterized by genetic heterogeneity and other mutated genes also been found in RPL5, RPL11, RPL35A, RPS7, RPS10, RPS17, RPS24, and RPS26, and rarely in RPL15, RPL17, RPL19, RPL26, RPL27, RPL31, RPS15A, RPS20, RPS27, RPS28, RPS29, and "non-RP" genes such as TSR2 and GATA1. TSR2 playS a role in ribosome biogenesis since it is involved in the pre-rRNA processing and binds to RPS26 and GATA1 which is the major erythroid transcription factor and plays a critical role in regulating normal erythroid differentiation by activating an array of erythroid genes. In the remaining 10-15% of DBA cases, no abnormal genes have yet been identified. It is likely that mutations are in a regulatory region including intronic regions and promoters in one of the known RP genes may account for the DBA phenotype. [3]
- Mutations in RP genes have been confirmed to be the direct cause of faulty erythropoiesis and anemia.[4].A generally documented pathogenetic hypothesis implies that a defective ribosome biosynthesis leads to apoptosis in erythroid progenitors which in turn is leading to erythroid failure. This mechanism has been named ‘‘ribosomal stress . in ‘‘ribosomal stress, reduced RP synthesis activates p53 that induces the downstream events and leads to cell cycle termination or apoptosis. Finally, this phenomenon results in the DBA phenotype of anemia, deprived growth, and results in congenital abnormalities. Mutated RP genes in DBA encode ribosomal proteins which are involved in either the small (RPS) or large (RPL) subunits of these proteins and the scarcity of these proteins can cause the development of the disease.[5]
References
- ↑ Ball S (2011). "Diamond Blackfan anemia". Hematology Am Soc Hematol Educ Program. 2011: 487–91. doi:10.1182/asheducation-2011.1.487. PMID 22160079.
- ↑ Garçon L, Ge J, Manjunath SH, Mills JA, Apicella M, Parikh S, Sullivan LM, Podsakoff GM, Gadue P, French DL, Mason PJ, Bessler M, Weiss MJ (August 2013). "Ribosomal and hematopoietic defects in induced pluripotent stem cells derived from Diamond Blackfan anemia patients". Blood. 122 (6): 912–21. doi:10.1182/blood-2013-01-478321. PMC 3739037. PMID 23744582.
- ↑ 3.0 3.1 Da Costa L, Narla A, Mohandas N (2018). "An update on the pathogenesis and diagnosis of Diamond-Blackfan anemia". F1000Res. 7. doi:10.12688/f1000research.15542.1. PMC 6117846. PMID 30228860.
- ↑ Vlachos A, Dahl N, Dianzani I, Lipton JM (October 2013). "Clinical utility gene card for: Diamond-Blackfan anemia--update 2013". Eur. J. Hum. Genet. 21 (10). doi:10.1038/ejhg.2013.34. PMC 3778360. PMID 23463023.
- ↑ Lipton JM, Ellis SR (April 2009). "Diamond-Blackfan anemia: diagnosis, treatment, and molecular pathogenesis". Hematol. Oncol. Clin. North Am. 23 (2): 261–82. doi:10.1016/j.hoc.2009.01.004. PMC 2886591. PMID 19327583.